Gene Therapy in Oncology Thematic Research Report 2021 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Gene Therapy in Oncology - Thematic Research" report has been added to ResearchAndMarkets.com's offering.

Gene therapy describes the treatment of various cancers with the use of in vivo treatments: viral and non-viral gene therapy products, therapeutic oligonucleotides, oncolytic viruses and genome editing therapies.

There are currently just 3 gene therapies marketed for oncology indications in the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China). Oncolytic viruses lead the category with 2 products, followed by viral vector gene therapies with 1 approved drug.

Gene therapies are in development for melanoma and other various solid tumors. As of April 2021, there are 252 clinical trials investigating in vivo gene therapies across the 8MM with 81 drugs in development.

Sales of products that comprise the categories of in vivo gene therapy are forecast to reach over $7B by 2027. The therapeutic oligonucleotide market, which will be galvanized by the success of COVID-19 messenger ribonucleic acid (mRNA) vaccines, is forecast to reach $4.5B by 2027 globally.

Key Highlights

Key Questions Answered

Scope

Key Topics Covered:

1. Preface

2. Executive Summary

2.1. Key Findings

3. Gene Therapy Overview

3.1. What is Gene Therapy?

3.2. History of Gene Therapy Development in Cancer in the 8MM

3.3. Key Twitter Chat

4. Trends

4.1. Industry Trends - Gene Therapy Vectors

4.2. Industry Trends - Therapeutic Oligonucleotides

4.3. Industry Trends - Genome Editing

4.4. Industry Trends - Oncolytic Viruses

4.5. Regulatory Trends

5. Value Chain

5.1. Gene Therapy Value Chain

5.2. Gene Therapy Vectors

5.3. Therapeutic Oligonucleotides

5.4. Genome Editing

5.5. Oncolytic Viruses

5.6. Gene Therapy in Oncology Clinical Trials

6. Marketed Products

6.1. Marketed Gene Therapy Products for Cancer in the 8MM

6.2. Leading Gene Therapy Treatments in The 8MM

7. Pipeline Products

7.1. Gene Therapy Pipeline Products in the 8MM

7.2. Gene Therapy Pipeline Candidates

7.3. Late Stage Gene Therapy Candidates, 8MM

8. Market Analysis and Deals

8.1. Gene Therapy Market Analysis and Forecast by Class of Therapy

8.2. Top 10 Transaction Deals by Size during 2012-2021 in the Oncology Gene Therapy Space

8.3. Latest Transaction Deals in the Oncology Gene Therapy Space

8.4. Mergers and Acquisitions That Include Oncology Gene Therapy Assets: 2019 - 2021

8.5. Mergers and Acquisitions That Include Oncology Gene Therapy Assets: 2014 - 2018

9. Regulatory and Market Access

9.1. Gene Therapy in Clinical Trials

9.2. Regulatory - US

9.3. Market Access - US

9.4. Regulatory - Europe

9.5. Market Access - Europe

9.6. Regulation of Gene Therapy in the US and Europe

9.7. Regulatory and Market Access - Japan

9.8. Comparison of Early Access Schemes in the US, EU, and Japan

9.9. Regulatory and Market Access - China

10. Opportunities, Challenges, and Unmet Needs

10.1. Gene Therapy Vectors, Viral - Opportunities & Challenges

10.2. Gene Therapy Vectors, Non-viral - Opportunities & Challenges

10.3. Therapeutic Oligonucleotides - Opportunities & Challenges

10.4. Genome Editing - Opportunities & Challenges

10.5. Oncolytic Viruses - Opportunities & Challenges

10.6. Clinical Unmet Needs in Gene Therapy - Gap Analysis

10.7. Commercial Unmet Needs in Gene Therapy - Gap Analysis

10.8. Unmet Needs - KOLs Perspective

11. Companies

11.1. Drug Development Scorecard - Regenerative Medicine

11.2. Current Major Players

11.2.1. Amgen

11.2.2. SiBiono

11.2.3. Sunway Biotech

11.3. Future Players Based on Pipeline Strength

11.3.1. Candel

11.3.2. CG Oncology

11.3.3. Checkmate

11.3.4. Daiichi Sankyo

11.3.5. Ferring

11.3.6. FKD

11.3.7. Geron

11.3.8. Idera

11.3.9. Istari

11.3.10. VBL

12. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/v0ma92

Continued here:
Gene Therapy in Oncology Thematic Research Report 2021 - ResearchAndMarkets.com - Business Wire